So if it does become available, how do you think it will be used in clinical practice?

It'll be used as a fourth-line drug.

I think it will be used in people who've tried either an ARB, calcium channel blocker, diuretic And still not reach target.

And so, it'll be an add-on therapy to them.

I think it'll be very quickly taken up by secondary care, particularly hypertension experts.

I certainly hope that it is available to primary care because otherwise, the majority of people that, that need it will not receive it.

We don't know how precisely it will be licensed or what NICE's position will be on this.

Should NICE change its targets to match those of the ESC?